Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Evommune Inc. (EVMN : NYSE)

• Company Description    Evommune Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. Evommune Inc. is based in PALO ALTO, Calif. Number of Employees: 48

• Price / Volume Information    Yesterday's Closing Price: $12.27 Daily Weekly Monthly 20 Day Moving Average: 370,113 shares Shares Outstanding: 36.29 (millions) Market Capitalization: $445.30 (millions) Beta: 52 Week High: $33.20 52 Week Low: $10.47 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.79% -12.40% 12 Week -41.12% -42.38% Year To Date -28.33% -36.44%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1841 Page Mill Road Suite 100 - Palo Alto,CA 94304 USA ph: 925-247-4481 fax: - investors@evommune.com http://www.evommune.com

• General Corporate Information    Officers Luis Pena - Chief Executive Officer and President Benjamin F. McGraw, III - Chairman Kyle Carver - Chief Financial Officer Eugene A. Bauer - Director Derek DiRocco - Director Peer Information Evommune Inc. (CORR.) Evommune Inc. (RSPI) Evommune Inc. (CGXP) Evommune Inc. (BGEN) Evommune Inc. (GTBP) Evommune Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 30054Y107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 12/10/26 Share - Related Items Shares Outstanding: 36.29 Most Recent Split Date: (:1) Beta: Market Capitalization: $445.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.82 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 12/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.59 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -39.06% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -62.63 03/31/26 - -92.96 12/31/25 - -1,228.23 ROA 06/30/26 - -40.55 03/31/26 - -48.10 12/31/25 - -89.01 Current Ratio 06/30/26 - 11.68 03/31/26 - 20.36 12/31/25 - 8.57 Quick Ratio 06/30/26 - 11.68 03/31/26 - 20.36 12/31/25 - 8.57 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - -946.68 03/31/26 - -759.87 12/31/25 - -529.77 Book Value 06/30/26 - 7.71 03/31/26 - 8.46 12/31/25 - 6.52 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.16 03/31/26 - 0.17 12/31/25 - 0.09

Powered by Zacks Investment Research ©